- Home
- CNF vs ALVR Comparison
CNF vs ALVR Comparison
Compare CNF & ALVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNF
- ALVR
- Stock Information
- Founded
- CNF 1999
- ALVR 2013
- Country
- CNF China
- ALVR United States
- Employees
- CNF N/A
- ALVR N/A
- Industry
- CNF Finance: Consumer Services
- ALVR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CNF Finance
- ALVR Health Care
- Exchange
- CNF Nasdaq
- ALVR Nasdaq
- Market Cap
- CNF 59.0M
- ALVR 48.8M
- IPO Year
- CNF 2018
- ALVR 2020
- Fundamental
- Price
- CNF $1.12
- ALVR $9.63
- Analyst Decision
- CNF
- ALVR
- Analyst Count
- CNF 0
- ALVR 0
- Target Price
- CNF N/A
- ALVR N/A
- AVG Volume (30 Days)
- CNF 22.5K
- ALVR 22.4K
- Earning Date
- CNF 03-27-2025
- ALVR 03-14-2025
- Dividend Yield
- CNF N/A
- ALVR N/A
- EPS Growth
- CNF N/A
- ALVR N/A
- EPS
- CNF 0.24
- ALVR N/A
- Revenue
- CNF $109,788,152.00
- ALVR N/A
- Revenue This Year
- CNF N/A
- ALVR N/A
- Revenue Next Year
- CNF $13.09
- ALVR N/A
- P/E Ratio
- CNF $4.67
- ALVR N/A
- Revenue Growth
- CNF 12.99
- ALVR N/A
- 52 Week Low
- CNF $0.81
- ALVR $7.96
- 52 Week High
- CNF $2.84
- ALVR $24.15
- Technical
- Relative Strength Index (RSI)
- CNF 47.25
- ALVR 45.63
- Support Level
- CNF $1.07
- ALVR $9.55
- Resistance Level
- CNF $1.23
- ALVR $10.41
- Average True Range (ATR)
- CNF 0.09
- ALVR 0.44
- MACD
- CNF -0.02
- ALVR 0.05
- Stochastic Oscillator
- CNF 20.87
- ALVR 22.77
About CNF CNFinance Holdings Limited each representing twenty (20)
CNFinance Holdings Ltd is an equity loan service provider. It focuses on the development of small and micro-enterprises. It generates revenue in the form of interest and financing service fees on loans and interest on deposits with banks. Its primary target borrower segment is MSE owners who own real properties in Tier 1 and Tier 2 cities in China. Geographically, it has an operation in PRC.
About ALVR AlloVir Inc.
AlloVir Inc is a late clinical-stage cell therapy company. The company focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform enables the creation of off-the-shelf VSTs, addressing the urgent medical need for treating patients with limited viral disease treatment options. With a singular focus on research, development, and commercialization, the company's platform targets 11 devastating viruses, with posoleucel being the lead candidate addressing six viruses. Operating within one segment, the company is dedicated to preventing and treating severe viral-associated diseases through off-the-shelf VST therapies.